Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature

References

• Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004;159:107–12
   PubMed Web of Science ®Google Scholar
• Gogou E, Kerenidi T, Chamos V, Zintzaras E, Gourgoulianis KI. Mesothelioma mortality in Greece from 1983 to 2003. Int J Clin Pract 2009;63(6):944–8
   PubMed Web of Science ®Google Scholar
• Reid A, de Klerk NH, Magnani C, Ferrante D, Berry G, Musk AW, et al. Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis. Thorax 2014;69:843–50
   PubMed Web of Science ®Google Scholar
• Thompson JK, Westbom CM, MacPherson MB, Mossman BT, Heintz NH, Spiess P, et al. Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation. Part Fibre Toxicol 2014;11:24
   PubMed Web of Science ®Google Scholar
• Cleaver AL, Bhamidipaty K, Wylie B, Connor T, Robinson C, Robinson BW, et al. Long-term exposure of mesothelial cells to SV40 and asbestos leads to malignant transformation and chemotherapy resistance. Carcinogenesis 2014;35:407–14
   PubMed Web of Science ®Google Scholar
• Browne K, Smither WJ. Asbestos-related mesothelioma: factors discriminating between pleural and peritoneal sites. Br J Ind Med 1983;40:145–52
   PubMedGoogle Scholar
• Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999;70: 6–12
   PubMed Web of Science ®Google Scholar
• Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988;6:147–53
   PubMed Web of Science ®Google Scholar
• Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007;18:827–34
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:686–91
   PubMed Web of Science ®Google Scholar
• Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, et al. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol 2006;17:1615–19
   PubMed Web of Science ®Google Scholar
• Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237–42
   PubMed Web of Science ®Google Scholar
• Levine EA, Stewart JH IV, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg 2014;218:573–85
   PubMed Web of Science ®Google Scholar
• Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2013;20:1093–100
   PubMed Web of Science ®Google Scholar
• Courcoutsakis N, Tentes AA, Astrinakis E, Zezos P, Prassopoulos P. CT-Enteroclysis in the preoperative assessment of the small-bowel involvement in patients with peritoneal carcinomatosis, candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Abdom Imaging 2013;38:56–63
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Management of Peritoneal Surface Malignancy Using Intraperitoneal Chemotherapy and Cytoreductive Surgery. A Manual for Physicians and Nurses, 3rd ed. Grand Rapids (MI): Ludann, 1998
   Google Scholar
• Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29–42
   PubMed Web of Science ®Google Scholar
• Weiss SW. World Health Organization, International Histological Classification of Tumors. Histological Typing of Soft Tissue Tumors, 2nd ed. Berlin: Springer Verlag, 1994
   Google Scholar
• Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology 1997;30:403–18
   PubMed Web of Science ®Google Scholar
• Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2013;20:1093–100
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 2009;99:109–13
   PubMed Web of Science ®Google Scholar
• Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, et al. Importance of gender in diffuse malignant peritoneal mesothelioma. Peritoneal Surface Malignancy Group. Ann Oncol 2012;23:1494–8
   PubMed Web of Science ®Google Scholar
• Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 2009;69:4598–604
   PubMed Web of Science ®Google Scholar
• Acherman YIZ, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269–73
   PubMed Web of Science ®Google Scholar
• Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006;13:229–37
   PubMed Web of Science ®Google Scholar
• Nonaka D, Kusamura S, Baratti D, Casali P, Cabras AD, Younan R, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer 2005;104:2181–8
   PubMed Web of Science ®Google Scholar
• Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007;14:41–9
   PubMed Web of Science ®Google Scholar
• Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005;103:839–49
   PubMed Web of Science ®Google Scholar
• Los G, Smals OA, van Vugt MJ, van der Vlist M, den Engelse L, McVie JG, et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 1992;52:1252–8
   PubMed Web of Science ®Google Scholar
• Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013;153:779–86
   PubMed Web of Science ®Google Scholar
• Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol 2010;17:2720–7
   PubMed Web of Science ®Google Scholar
• Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW. Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg 2014;80:348–52
   PubMed Web of Science ®Google Scholar
• Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Open–label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005;7:40–6
   PubMed Web of Science ®Google Scholar
• Bijelic L, Stuart OA, Sugarbaker P. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Pract 2012;2012:890450
   PubMed Web of Science ®Google Scholar
• Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 2006;13:405–12
   PubMed Web of Science ®Google Scholar
• Langer CJ, Rosenblum N, Hogan M, Nash S, Bagchi P, LaCreta FP, et al. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 1993;32:204–8
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140–8
   PubMed Web of Science ®Google Scholar